Monographs / DPP-4 Inhibition: Playing the Long Game in Type 2 Diabetes


expert
Clinician Scientist; Program Leader, Department of Diabetes, Monash University
This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.
Written by Prof Merlin Thomas MBChB, PhD, FRACP
Prof Merlin Thomas is a Professor of Medicine at Monash University, Melbourne. Professor Thomas is both a physician and a research scientist. He has published over 300 articles in many of the world’s leading medical journals, as well as several books including The Longevity List and Fast Living, Slow Ageing. He is internationally recognised as a speaker, opinion-leader, teacher and medical storyteller. His research focuses on discovering new ways to prevent and treat the complications of diabetes.

GLP 1s & Sarcopenia: Fact vs Hype

The New Dengue Vaccine – What You Need to Know

Hypertriglyceridaemia – Causes, Assessment & Management of CV Risk

Management of Photoageing

expert
Clinician Scientist; Program Leader, Department of Diabetes, Monash University



A great extent
A moderate extent
Slightly
Not at all
Listen to expert interviews.
Click to open in a new tab
Browse the latest monographs from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.